Why is Novartis India Ltd falling/rising?

Strong Market Outperformance Drives Investor Interest

Novartis India’s recent price action stands out distinctly against the backdrop of the broader market. Over the past week, the stock has gained 25.79%, vastly outperforming the Sensex’s modest 0.23% rise. This trend extends over longer periods as well, with the stock delivering a 27.67% return in the last month compared to the Sensex’s 0.77%, and a year-to-date gain of 27.92% while the benchmark index declined by 2.82%. Even on a one-year basis, Novartis India has generated a 19.17% return, doubling the Sensex’s 9.35% gain. These figures underscore the stock’s resilience and appeal amid volatile market conditions.

Today’s trading session further highlighted this momentum. The stock opened with an 8.86% gap up and reached an intraday high of Rs 996.50, marking a 20% increase on the day. Despite a wide trading range of Rs 92.5, the stock maintained strength above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day levels, signalling sustained bullish sentiment among traders and investors.

Fundamental Strengths Support Price Appreciation

Novartis India’s long-term fundamentals provide a solid foundation for its recent price gains. The company boasts a zero debt-to-equity ratio, indicating a clean balance sheet with no leverage risk. Operating profit has grown at an impressive annual rate of 57.68%, reflecting strong operational efficiency and business expansion. This robust growth trajectory has translated into market-beating returns, with the stock outperforming the BSE500 index consistently over the past three years, one year, and three months.

Additionally, the stock offers a relatively attractive dividend yield of 3.01% at the current price, which may appeal to income-focused investors seeking steady returns alongside capital appreciation. Liquidity remains adequate for trading, with the stock able to handle trade sizes of approximately Rs 0.06 crore based on recent average volumes.

However, it is noteworthy that despite these positives, investor participation has shown signs of moderation. Delivery volumes have declined by 38.63% compared to the five-day average, suggesting some caution among shareholders or a shift in trading patterns.

Challenges Tempering Enthusiasm

Despite the strong price performance, certain fundamental concerns persist. The company reported negative quarterly results for the period ending 25 Dec, with profit after tax (PAT) falling sharply by 36.8% to Rs 16.09 crore. Net sales also declined by 7.63% in the same quarter, signalling potential headwinds in revenue generation. The debtors turnover ratio, a measure of how efficiently the company collects receivables, was at a low 7.28 times for the half-year, which may indicate slower cash conversion cycles.

Valuation metrics suggest the stock is trading at a premium, with a price-to-book value of 3.2 and a return on equity (ROE) of 12.5%. While these figures are within a reasonable range compared to peers, the company’s price-to-earnings growth (PEG) ratio stands at 2, implying that the stock’s price growth may be outpacing earnings growth. This could raise concerns about the sustainability of the current valuation.

Moreover, domestic mutual funds hold a negligible stake of just 0.01%, which may reflect limited institutional conviction or caution regarding the company’s prospects or valuation at current levels.

Conclusion: A Stock Riding Strong Momentum Amid Mixed Fundamentals

Novartis India Ltd’s 20% price surge on 20-Feb is primarily driven by its exceptional market outperformance and strong long-term growth fundamentals. The stock’s ability to outperform the Sensex and its sector consistently over multiple time frames has attracted investor interest, supported by a clean balance sheet and impressive operating profit growth. However, recent quarterly results showing declines in PAT and net sales, coupled with a relatively high valuation and limited institutional ownership, suggest caution for investors.

While the stock’s momentum remains robust, prospective investors should weigh the current premium valuation against the company’s recent earnings challenges and market positioning. The stock’s high dividend yield and liquidity add to its appeal, but the mixed signals from fundamentals and investor participation warrant careful analysis before committing capital.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →